Monday, June 27, 2022 9:19:08 AM
"One bit of news is that the U.S. Food and Drug Administration (FDA) has banned the sale of Juul ecigarettes from the United States market. Apart from the fact that Juul did not provide the data needed to convince the FDA to allow marketing to continue. There may have been a little bit of vindictiveness in the FDA’s action as it also mentioned that Juul had a disproportionate impact on youth vaping. Altria also has an interest in Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW) nicotine. Although having their $12.8 billion investment in Juul effectively incinerated it may change Altria’s direction toward ingested delivery of nicotine.
"Lexaria Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW) announced signing two agreements with
Atlanta-based BevNology LLC ("BevNology").
1. The first agreement is a manufacturing operating agreement that expands production capabilities for LEXX’s own growing list of business-to-business (B2B) clientele interested in
purchasing DehydraTECH-powered active ingredients for consumer packaged-goods
brands. A new, state-of-the-art processing facility custom-built by BevNology is operational
that increases and broadens production capacity and is currently serving Lexaria's corporate clients. Lexaria has moved and installed all required commercial DehydraTECH manufacturing equipment into BevNology's new facility as it prepares for future growth in its B2B ingredient processing business.
2. The second agreement is a commercial license empowering BevNology to offer DehydraTECH products with active ingredients derived from hemp including cannabidiol (CBD) under BevNology and partnered brands. For powdered DehydraTECH formulations this agreement is non-exclusive. For liquid
ehydraTECH formulations, where BevNology has
highly specialized skills and capabilities, the license is non-exclusive in most areas of the
world but includes limited exclusivity rights in the U.S. only that require certain minimum
fee payments in order to maintain those rights. Lexaria will receive royalties from BevNology as a result of their utilization of this license. The only countries specifically excluded
under this license are Japan, the Republic of Korea, and the People's Republic of China.
"These are two separate agreements. The first is a new agreement to have BevNology manufacture the products that LEXX sells to commercial customers in facilities that LEXX CEO describes as “class leading.” The second is a more conventional commercial contract that licenses BevNology to use LEXX’s technology in return for royalties on sales.
Conclusion: I recently described the series of recent commercial agreements announced by Lexaria
Bioscience (NASDAQ: LEXX) (NASDAQ: LEXXW) as adding grains of sand on the scales measuring LEXX’s valuation in the market. You never know which deal causes the scale to turn sharply in LEXX’s favour. It is clear, however, that shift is taking place."
Here is some news that impacted LEXX just this month.
• June 21, 2022: BevNology commercial and manufacturing contract.
• June 17, 2022: I reported between June 6 - 17, 2022 the number of LEXX reported short sales divided by the total volume of off exchange trading declined sharply from a Short Volume Ratio of 43.67 to 8.18. The Short Volume Ratio is the Short Volume divided by Total off exchange Volume reported.
• June 8, 2022: AnodGen Bioceuticals commercial sales agreement
• June 6, 2022: Pre-IND meeting request letter with U.S. Food and Drug Administration
• June 3, 2022: Premier Wellness Science sales agreement including Premier’s worldwide independent assessment of DehydraTECH™ as their technology of choice
• June 2, 2022: Valcon Medical in the European Market
13
Conclusion: It appears to me that the recent acceleration in LEXX’s B2B commercial sales have not
been lost on investors. At the same time, the even more explosive growth potential comes from the steps taken on the hypertension front with the U.S. FDA.
What investors see is the increasing credibility of LEXX’s business model to generate sufficient B2B royalty revenue to sustain operations. It should not be forgotten that royalty revenue is the equivalent of gross profit for other operators because there is no ‘cost of goods sold’ associated.
Finally, investors should remember that the business plan always contemplated separating the different
applications of the technology. This means the DehydraTECH™ application in CBD is separate from its application in nicotine that is separate from antiviral drugs that is separate from PDE5 inhibitors and more. The “blue sky” implication is with hypertension it is possible that LEXX could replicate the GW
Pharma success or see it completed by a partner and it is within the realm of possibility that it could be repeated many times over. All of this is speculative but it is, at least, within the realm of possibilities.
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_c36ce2a24ea94e54bae68b89f35a09f2.pdf
Recent LEXX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 02:55:35 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/06/2024 08:11:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 04:25:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 03:32:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 03:12:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/17/2024 08:12:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/12/2024 05:26:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/06/2024 11:00:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 07:28:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:30:59 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/16/2024 08:47:26 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 05:00:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 06:51:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 07:12:07 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/24/2024 06:33:08 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/18/2024 07:38:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/12/2024 10:11:16 PM
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream • GlobeNewswire Inc. • 01/11/2024 01:30:00 PM
- Beyond Diabetes, a Blockbuster Horizon Beckons • InvestorsHub NewsWire • 01/10/2024 01:45:00 PM
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform • GlobeNewswire Inc. • 01/09/2024 01:30:00 PM
- Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs • InvestorsHub NewsWire • 01/08/2024 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 10:07:45 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM